Circadian timing optimizes allo-HSCT to prevent aGVHD: a breakthrough in chrono-immunotherapy.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely regarded as the most potent curative cell therapy for a range of malignancies, particularly hematologic cancers. However, its clinical application remains significantly constrained by acute graft-versus-host disease (aGVHD), a severe and potentially fatal complication. As such, developing more effective strategies to prevent and manage aGVHD has become an urgent priority in the field. In a groundbreaking study, the team led by Zhan Cheng and Zhu Xiaoyu introduced a novel time-based approach, revealing that the biological rhythm regulating the immune microenvironment can be harnessed to optimize the timing of hematopoietic stem cell infusion. Their findings demonstrate that this chronotherapeutic strategy can significantly reduce the incidence of aGVHD, offering a simple, drug-free, and cost-free innovation to improve outcomes in allo-HSCT.